TuHURA Biosciences (NASDAQ:HURA) Stock Rating Lowered by Wall Street Zen

TuHURA Biosciences (NASDAQ:HURA) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Sunday.

A number of other brokerages have also recently weighed in on HURA. Weiss Ratings restated a “sell (e+)” rating on shares of TuHURA Biosciences in a report on Wednesday, October 8th. Maxim Group cut their price target on TuHURA Biosciences from $15.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, November 14th. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, TuHURA Biosciences presently has an average rating of “Buy” and an average target price of $10.33.

TuHURA Biosciences Trading Down 6.0%

HURA opened at $0.96 on Friday. The company has a market cap of $49.38 million, a price-to-earnings ratio of -1.93 and a beta of -0.03. The stock has a fifty day simple moving average of $2.11 and a two-hundred day simple moving average of $2.44. TuHURA Biosciences has a 12-month low of $0.93 and a 12-month high of $5.50.

TuHURA Biosciences (NASDAQ:HURA) last announced its earnings results on Friday, November 14th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01.

Institutional Investors Weigh In On TuHURA Biosciences

Several institutional investors have recently modified their holdings of the business. Geode Capital Management LLC increased its holdings in TuHURA Biosciences by 111.4% in the 2nd quarter. Geode Capital Management LLC now owns 582,992 shares of the company’s stock worth $1,300,000 after buying an additional 307,260 shares in the last quarter. New York State Common Retirement Fund purchased a new stake in shares of TuHURA Biosciences during the 2nd quarter valued at about $97,000. Marshall Wace LLP purchased a new stake in shares of TuHURA Biosciences during the 2nd quarter valued at about $79,000. Vanguard Group Inc. grew its stake in shares of TuHURA Biosciences by 1.6% in the third quarter. Vanguard Group Inc. now owns 2,269,666 shares of the company’s stock worth $5,629,000 after acquiring an additional 35,426 shares during the period. Finally, Brighton Jones LLC purchased a new position in shares of TuHURA Biosciences during the third quarter valued at approximately $69,000. 0.62% of the stock is owned by hedge funds and other institutional investors.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.